J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
J&J has found its next big cancer drug. In China.
The pharma giant has agreed to pay $350 million upfront to partner with Legend Biotech to develop its BCMA-targeting CAR-T LCAR-B38M for multiple myeloma.
Don’t know Legend? You should.
The virtually unknown biotech wowed ASCO with early-stage data on its CAR-T and clearly caught J&J’s attention. The deal vaults J&J into an intensely competitive race to get the first BCMA cell therapy to an approval, with bluebird bio in the lead and Juno and others in hot pursuit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.